Roche Diagnostics plans to pour more than $258 million into building a new diagnostics production complex in Germany, thanks to rising demand for immunoassays of all kinds.
Biomarkers play a major role in personalized medicine, supporting diagnosis and identifying those patients who are (or aren't) likely to respond, and supporting drugs through clinical trials.
GNS Healthcare has teamed up with Dana-Farber and Mount Sinai to build a Big Data-driven computer model of multiple myeloma. The project will combine GNS' computing power with data from next-generation sequencing to support the development of personalized medicines.
Advanced Cell Diagnostics is kicking up a major expansion now that it has reeled in a $12 million Series B round of financing.
The move gives the consulting giant the keys to Newton, MA-based Recombinant Data's growing business that serves the data needs of hospitals, research institutions and healthcare companies.
A group from the University of California, Santa Cruz, has embarked on a new project to commercialize cancer genomics software through a new startup company called Five3 Genomics. The company has attracted a few of the biggest names in genomics and biotech to serve as advisers.
The Pittsburgh-based health group has tapped Oracle, IBM, Informatica and dbMotion for technology in the $100 million project, which will give clinicians, researchers, administrators and others real-time access to data and analytics, UPMC announced Oct. 1.
Life Technologies ($LIFE) just sealed a multi-year deal with CollabRx ($CLRX) intended to supercharge the value of its molecular diagnostics tests with lots of data.
There's a new trend in research: using mice as avatars, or stand-ins, of sorts--personal guinea pigs for patients seeking the best possible cancer treatment.
A finding that there are four main genetic subtypes of breast cancer creates enormous new opportunities for diagnostics companies. And the research, conducted by the Cancer Genome Atlas project and published in the journal Nature, could further upend the diagnostics industry as the science behind personalized medicine continues to advance, Bloomberg reports.